15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $1.9B | -$713M | 98.6% | -37.5% | -$307M | $829M | $801M |
| 2024 | $1.8B | $235M | 0.0% | 12.2% | -$343M | $1.1B | $1.1B |
| 2023 | $1.1B | -$536M | 0.0% | -23.4% | -$577M | $1.2B | $428M |
| 2022 | $844M | -$703M | 0.0% | -63.5% | -$356M | $1.5B | $967M |
| 2021 | $612M | -$419M | 0.0% | -75.1% | -$482M | $564M | $2.1B |
| 2020 | $456M | -$554M | 0.0% | -123.8% | $25M | — | $1.5B |
| 2019 | $381M | -$715M | 0.0% | -185.3% | -$516M | — | $835M |
| 2018 | $301M | -$362M | 0.0% | -114.1% | -$450M | $421M | $371M |
| 2017 | $155M | -$51M | 0.0% | -111.0% | -$244M | $431M | $600M |
| 2016 | $5M | -$267M | 0.0% | -4920.3% | -$251M | $18M | $122M |
| 2015 | — | -$220M | — | — | — | $27M | $80M |
| 2014 | — | -$136M | — | — | — | $7M | $74M |
| 2014 | — | -$572M | — | — | — | $2M | $49M |
| 2013 | — | -$112M | — | — | -$67M | $2M | $257M |
| 2013 | — | -$534M | — | — | -$329M | $2M | $274M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $331M | $331M | 0.0% | 108.4% | -$205M | $838M | $464M |
| Dec '25 | $370M | -$412M | -7.9% | -111.4% | $128M | $829M | $801M |
| Sep '25 | $370M | -$51M | 59.3% | -27.9% | -$38M | $141M | $613M |
| Jun '25 | $513M | $197M | 70.3% | 22.5% | $230M | — | $511M |
| Mar '25 | $612M | -$448M | 77.5% | -49.1% | -$627M | — | $241M |
| Dec '24 | $638M | $159M | 79.3% | 25.3% | $54M | $1.1B | $1.1B |
| Sep '24 | $430M | $34M | 78.7% | 5.2% | -$108M | $1.2B | $198M |
| Jun '24 | $361M | $6M | 87.6% | -0.2% | -$14M | $1.2B | $384M |
| Mar '24 | $359M | $36M | 85.9% | 9.7% | -$275M | $1.2B | $427M |
| Dec '23 | $365M | $46M | 0.0% | 6.7% | -$74M | $1.2B | $428M |
| Sep '23 | $309M | -$41M | 0.0% | -6.7% | -$144M | $1.2B | $542M |
| Jun '23 | $239M | -$24M | 0.0% | -55.9% | -$140M | $1.2B | $852M |
| Mar '23 | $231M | -$517M | 0.0% | -59.7% | -$219M | $1.2B | $872M |
| Dec '22 | $236M | -$109M | 0.0% | -45.3% | -$100M | $1.5B | $967M |
| Sep '22 | $208M | -$258M | 0.0% | -63.2% | -$73M | $1.5B | $1.0B |
| Jun '22 | $211M | -$231M | 0.0% | -100.0% | -$76M | — | $869M |
| Mar '22 | $189M | -$105M | 0.0% | -46.0% | -$107M | — | $1.2B |
| Dec '21 | $179M | -$122M | 0.0% | -59.2% | -$32M | $564M | $2.1B |
| Sep '21 | $167M | -$48M | 0.0% | -20.6% | -$134M | — | $1.6B |
| Jun '21 | $142M | -$81M | 0.0% | -118.1% | -$115M | — | $1.7B |
How the market has priced SRPT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Sarepta Therapeutics, Inc.'s revenue has grown 32.5% per year. These are computed facts, not advice.
As of FY2025, Sarepta Therapeutics, Inc. reported $829M of total debt against $801M of cash; operating income covered interest expense 18×.
In FY2025, gross margin was 98.6%, operating margin -37.5%, and net margin -38.3%.
As of Jun '26, Sarepta Therapeutics, Inc. traded at a price-to-earnings ratio of about 9.6× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.